IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v5y2021i3d10.1007_s41669-021-00289-0.html
   My bibliography  Save this article

Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs

Author

Listed:
  • James F. O’Mahony

    (Trinity College Dublin)

Abstract

Ireland’s cost-effectiveness threshold is currently €45,000 per quality-adjusted life-year (QALY). It has previously been determined by periodic agreements between the State and a pharma industry lobby body. A new deal is due in July 2021 and it is therefore timely to re-examine Ireland’s threshold, how it is set and transparency around adherence to it. Previous research has noted a series of problems with the threshold, including that it is likely too high relative to the opportunity cost of unmet need within Ireland’s health system. This means reimbursement at the threshold may do net harm to population health. The high threshold may also mean the Irish health system is failing to satisfy existing legislation on healthcare resource allocation. Recent COVID-19-related pressures on healthcare capacity and public spending appear to increase the urgency for an evidence-based revision of threshold to better reflect opportunity costs within the Irish healthcare system. Despite these problems, the prospects for reform of the threshold do not appear strong as the political and institutional incentives may favour the status quo. At the very least, the State should provide greater transparency regarding how the threshold is set and adhered to. A potential reform for consideration in the longer run could include a partial abandonment of thresholds in favour of an auction process to achieve the lowest cost per QALY from new drug interventions.

Suggested Citation

  • James F. O’Mahony, 2021. "Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs," PharmacoEconomics - Open, Springer, vol. 5(3), pages 339-348, September.
    • Handle: RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00289-0
    DOI: 10.1007/s41669-021-00289-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-021-00289-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-021-00289-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Brick, Aoife & Gorecki, Paul K. & Nolan, Anne, 2013. "Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context," Research Series, Economic and Social Research Institute (ESRI), number RS32.
    2. Franken, Margreet & Stolk, Elly & Scharringhausen, Tessa & de Boer, Anthonius & Koopmanschap, Marc, 2015. "A comparative study of the role of disease severity in drug reimbursement decision making in four European countries," Health Policy, Elsevier, vol. 119(2), pages 195-202.
    3. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    4. Whyte, Richard & Connolly, Sheelah & Wren, Maev-Ann, 2020. "Insurance status and waiting times for hospital-based services in Ireland," Health Policy, Elsevier, vol. 124(11), pages 1174-1181.
    5. Bate, Angela & Donaldson, Cam & Murtagh, Madeleine J., 2007. "Managing to manage healthcare resources in the English NHS? What can health economics teach? What can health economics learn?," Health Policy, Elsevier, vol. 84(2-3), pages 249-261, December.
    6. Whyte, Richard & Connolly, Sheelah & Wren, Maev-Ann, 2020. "Insurance status and waiting times for hospital-based services in Ireland," Papers RB202021, Economic and Social Research Institute (ESRI).
    7. repec:bla:ausecr:v:37:y:2004:i:1:p:3-11 is not listed on IDEAS
    8. Wren, Maev-Ann, 2004. "Health Spending and the Black Hole," Quarterly Economic Commentary: Special Articles, Economic and Social Research Institute (ESRI), vol. 2004(3-Autumn), pages 1-23.
    9. Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & Andr, 2020. "Integrative Review of Managed Entry Agreements: Chances and Limitations," PharmacoEconomics, Springer, vol. 38(11), pages 1165-1185, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Connolly, Sheelah & Brick, Aoife & O'Neill, Ciarán & O'Callaghan, Michael, 2022. "An analysis of the primary care systems of Ireland and Northern Ireland," Research Series, Economic and Social Research Institute (ESRI), number RS137.
    2. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    3. Nolan, Anne & May, Peter & Matthews, Soraya & Normand, Charles & Kenny, Rose Anne & Ward, Mark, 2022. "Public health insurance and mortality in the older population: Evidence from the Irish Longitudinal Study on Ageing," Health Policy, Elsevier, vol. 126(3), pages 190-196.
    4. Penno, Erin & Sullivan, Trudy & Barson, Dave & Gauld, Robin, 2021. "Private choices, public costs: Evaluating cost-shifting between private and public health sectors in New Zealand," Health Policy, Elsevier, vol. 125(3), pages 406-414.
    5. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    6. Neale Smith & Craig Mitton & Stuart Peacock, 2009. "Qualitative methodologies in health‐care priority setting research," Health Economics, John Wiley & Sons, Ltd., vol. 18(10), pages 1163-1175, October.
    7. Holmes, Richard D. & Bate, Angela & Steele, Jimmy G. & Donaldson, Cam, 2009. "Commissioning NHS dentistry in England: Issues for decision-makers managing the new contract with finite resources," Health Policy, Elsevier, vol. 91(1), pages 79-88, June.
    8. Stuart J. Peacock & Craig Mitton, 2012. "Priority Setting Methods in Health Services," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 53, Edward Elgar Publishing.
    9. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    10. Miriam M. Wiley, 2005. "The Irish health system: developments in strategy, structure, funding and delivery since 1980," Health Economics, John Wiley & Sons, Ltd., vol. 14(S1), pages 169-186, September.
    11. A. ConwayLenihan & S. Ahern & S. Moore & J. Cronin & N. Woods, 2016. "Factors influencing the variation in GMS prescribing expenditure in Ireland," Health Economics Review, Springer, vol. 6(1), pages 1-8, December.
    12. Han, Euna & Chae, Su-Mi & Kim, Nam-Soon & Park, Sylvia, 2015. "Effects of pharmaceutical cost containment policies on doctors’ prescribing behavior: Focus on antibiotics," Health Policy, Elsevier, vol. 119(9), pages 1245-1254.
    13. Broqvist, Mari & Sandman, Lars & Garpenby, Peter & Krevers, Barbro, 2018. "The meaning of severity – do citizenś views correspond to a severity framework based on ethical principles for priority setting?," Health Policy, Elsevier, vol. 122(6), pages 630-637.
    14. Mulligan, Karen & Baid, Drishti & Doctor, Jason N. & Phelps, Charles E. & Lakdawalla, Darius N., 2024. "Risk preferences over health: Empirical estimates and implications for medical decision-making," Journal of Health Economics, Elsevier, vol. 94(C).
    15. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    16. Callan, Tim & Nolan, Brian, 2004. "Relative Income Poverty: Learning from the Best-Performing Countries," Papers BP2005/2, Economic and Social Research Institute (ESRI).
    17. Paul K. Gorecki, 2017. "Availability and Pricing New Medicines in Ireland: Reflections and Reform," PharmacoEconomics, Springer, vol. 35(10), pages 981-987, October.
    18. Katie Breheny & Emma Frew & Iestyn Williams & Sandra Passmore & Joanna Coast, 2020. "Use of Economic Evidence When Prioritising Public Health Interventions in Schools: A Qualitative Study with School Staff," IJERPH, MDPI, vol. 17(23), pages 1-11, December.
    19. Huang Weiting & Alwin Zhang Yaoxian & Yeo Khung Keong & Shao Wei Lam & Lau Yee How & Anders Olof Sahlén & Ahmadreza Pourghaderi & Matthew Che & Chua Siang Jin Terrance & Nicholas Graves, 2022. "The clinical value and cost-effectiveness of treatments for patients with coronary artery disease," Health Economics Review, Springer, vol. 12(1), pages 1-8, December.
    20. Maximilian H. M. Hatz & Jonas Schreyögg & Aleksandra Torbica & Giuseppe Boriani & Carl R. B. Blankart, 2017. "Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 124-144, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00289-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.